ClinicalTrials.Veeva

Menu

A Prospective, Single-center, Open-label Study of Inhaled BMD003 (CFTR mRNA) in Chinese Adults With Cystic Fibrosis

Chinese Academy of Medical Sciences & Peking Union Medical College logo

Chinese Academy of Medical Sciences & Peking Union Medical College

Status and phase

Active, not recruiting
Early Phase 1

Conditions

Gene Therapy
Cystic Fibrosis (CF)

Treatments

Drug: inhaled BMD003(CFTR mRNA)

Study type

Interventional

Funder types

Other

Identifiers

NCT06963008
BMD003-001

Details and patient eligibility

About

The study uses a prospective, single-center, open-label clinical trial design to evaluate the safety and efficacy of inhaled BMD003 (CFTR mRNA) in adult Chinese patients with cystic fibrosis.

This is a single-dose escalation study of nebulized inhaled BMD003 in patients with cystic fibrosis. The trial adopts sequential dose-escalation cohorts with flexible subject enrollment. Continuous safety monitoring will be performed throughout the study. If treatment-related adverse events meeting specified grade criteria occur during the trial, additional subjects will be enrolled at the current dose level for further safety observation. Subsequent dose escalation will proceed following a comprehensive safety evaluation of the prior cohort.

The trial consists of three phases: a 2-week screening period, a 1-day drug administration period, and a long-term follow-up period of approximately 13 months. After successful screening and meeting eligibility criteria, subjects will be admitted on Day 1 to receive nebulized inhalation of the investigational product. Comprehensive safety observations will be completed on Day 2 prior to hospital discharge.

Pharmacokinetic sampling and systematic safety assessments will be conducted at predefined study visits. All subjects will complete protocol-specified follow-up procedures after single-dose administration. Upon completion of this single-dose escalation phase, a multiple-dose study of BMD003 will be initiated. The detailed multiple-dose regimen will be defined based on preclinical findings and clinical data from this single-dose study, and implemented after ethical review and approval.

Full description

This is a prospective, single-center, open-label, single-dose-escalation clinical trial designed to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of nebulized inhaled BMD003 (CFTR mRNA) in adult patients with cystic fibrosis.

The study adopts a sequential cohort dose-escalation design. Enrollment flexibility is applied to ensure adequate safety observation at each study level. Continuous safety monitoring will be conducted throughout the screening, dosing, and follow-up phases. Dose escalation to the next cohort will only be permitted after completion of a predefined safety observation period and comprehensive safety review of the previous dose level. Additional subjects may be enrolled within the current cohort if significant treatment-related adverse events are observed, to further characterize the safety profile of BMD003.

Each eligible subject will complete a screening period of up to 2 weeks to confirm study eligibility. Qualified participants will be hospitalized for study drug administration on Day 1. Subjects will receive a single nebulized inhalation of BMD003 under medical supervision. In-hospital safety observation will be conducted for 24 hours after dosing, and subjects will be discharged upon satisfactory safety assessment on Day 2.

Pharmacokinetic blood sampling, vital sign monitoring, physical examinations, laboratory tests, and adverse event recording will be performed at scheduled time points throughout the study. After discharge, subjects will continue long-term follow-up for approximately 13 months to monitor delayed safety events and collect continuous clinical outcome data.

Following completion of this single-dose escalation study, a multiple-dose clinical investigation of BMD003 will be conducted. The dosing regimen, dosing frequency, and study design of the multiple-dose phase will be determined based on preclinical study results and the clinical safety and PK data obtained from this single-dose trial, and will be implemented after ethical approval.

Enrollment

12 estimated patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Patients must meet all of the following inclusion criteria to be included in this study:

  1. Gender not limited, 18 years old and above (including threshold values);
  2. The subjects themselves agree to participate in the study and sign an informed consent form
  3. Diagnosed with cystic fibrosis (CF);
  4. According to the investigators' assessment, the subject's cystic fibrosis disease is clinically stable;
  5. During screening, the subject's body mass index (BMI) is ≥ 17.5 kg/m ² and their weight is ≥ 40 kg;
  6. Forced Expiratory Volume in 1 second (FEV1) is expected to be ≥ 40% of the normal value;
  7. Resting oxygen saturation (SpO2) ≥ 92%;
  8. Quit smoking for at least 2 years;
  9. The subjects are willing and able to comply with the scheduled visits, treatments, laboratory tests, contraception requirements, and other study procedures.

Exclusion criteria

Individuals who meet any of the following criteria are not eligible for inclusion in this study:

  1. Acute respiratory infection, acute exacerbation of lung disease, clinically significant hemoptysis (>30 mL, or as determined by the investigator), or changes in respiratory medications (including antibiotics, oral steroids, etc.) used to treat CF occurred within 4 weeks prior to the first administration;

  2. Infected with highly virulent bacteria associated with accelerated decline in lung function and/or shortened survival time (e.g. Burkholderia cepacia, Mycobacterium abscesses). For subjects with a positive culture history, they can be considered uninfected according to the following guidelines:

    All culture results obtained in the past 12 months have been negative. Subject should have undergone at least 2 cultures within the past 12 months, with a minimum interval of 3 months between each culture, and at least one culture should have been conducted within 6 months prior to screening in this study.

  3. During screening, the 12 lead electrocardiogram showed prolonged QTcF interval (>450 ms for males and>460 ms for females) and clinically significant abnormalities in other indicators of the 12 lead electrocardiogram.

  4. During screening, total bilirubin exceeded the upper limit of normal, ALT and AST exceeded three times the upper limit of normal, and blood creatinine (CRE) was ≥ 1.5 times the upper limit of normal.

  5. History of physical organ or blood transplantation or registered waiting for transplantation;

  6. During screening, positive for human immunodeficiency virus antibodies (HIV Ab) and positive for Treponema pallidum specific antibodies (TPPA);

  7. Participated in inhalation drug or device studies within 30 days prior to the initial screening visit (a 30 day window period applies to inhalation drugs with elimination half-life<6 days. If the elimination half-life of inhalation drugs is ≥ 6 days, the window period should be extended to at least 5 half lives after the last administration);

  8. Pregnant (positive blood pregnancy test result) or lactating women;

  9. Having a history of drug allergies or other allergies, which investigators consider to be contraindications for participation in the study;

  10. History of drug allergies or other allergies, and investigators believe it contraindications for participation in the study;

  11. Investigators believe that any medical indicators (including other laboratory test indicators with clinical significance) or other conditions that may affect clinical trials.

Trial design

Primary purpose

Treatment

Allocation

N/A

Interventional model

Single Group Assignment

Masking

None (Open label)

12 participants in 1 patient group

inhaled BMD003(CFTR mRNA)
Experimental group
Description:
Single-dose nebulized inhalation of BMD003 (CFTR mRNA). This is a sequential dose-escalation cohort study. Subjects receive a single administration of the investigational product on Day 1, followed by safety and PK assessments during screening, in-hospital observation, and long-term follow-up.
Treatment:
Drug: inhaled BMD003(CFTR mRNA)

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems